We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $439M Turnover 36.22%
1-Year Est. Return 289.78%
This Fund
S&P 500
This Quarter Est. Return
+35.32%
1 Year Est. Return
+289.78%
3 Year Est. Return
+622.25%
5 Year Est. Return
+856.34%
10 Year Est. Return
+2,866.86%
AUM
$439M
AUM Growth
+$76.4M
Cap. Flow
-$4.42M
Cap. Flow %
-1.01%
Top 10 Hldgs %
28.21%
Holding
185
New
29
Increased
50
Reduced
66
Closed
38
Avg Time Held
1.1 years
Top 10 Avg Time Held
0.5 years
Top 20 Avg Time Held
0.5 years

Top Buys

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$4.61M
2
ALKS icon
Alkermes
ALKS
+$4.14M
3
TNGX icon
Tango Therapeutics
TNGX
+$3.85M
4
RLMD icon
Relmada Therapeutics
RLMD
+$3.12M
5
ELVN icon
Enliven Therapeutics
ELVN
+$2.75M

Top Sells

Rank Stock Value
1
TERN icon
Terns Pharmaceuticals
TERN
+$6.03M
2
NUVL icon
Nuvalent
NUVL
+$5.8M
3
SLNO icon
Soleno Therapeutics
SLNO
+$5.53M
4
SYRE icon
Spyre Therapeutics
SYRE
+$5M
5
APGE icon
Apogee Therapeutics
APGE
+$3.01M

Sector Composition

Rank Sector Weight
1 Healthcare 70.95%
2 Technology 8.26%
3 Miscellaneous 6.43%
4 Industrials 4.96%
5 Financials 2.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
DBC icon
1
Invesco DB Commodity Index Tracking Fund
DBC
$1.98B
$28.2M 6.43%
1,057,238
– –
2018 Q4
30 quarters
ABVX icon
2
Abivax
ABVX
$7.72B
$15.1M 3.43%
113,031
-223
-0.2% -$25.2K
2024 Q1
9 quarters
RVMD icon
3
Revolution Medicines
RVMD
$38.6B
$12.5M 2.86%
66,983
-2,326
-3% -$340K
2023 Q3
11 quarters
DFTX icon
4
Definium Therapeutics
DFTX
$4.36B
$11.4M 2.6%
242,884
+57,028
+31% +$1.41M
2026 Q1
1 quarter
IMVT icon
5
Immunovant
IMVT
$5.55B
$10.7M 2.44%
277,873
+52,734
+23% +$1.61M
2025 Q1
5 quarters
PRAX icon
6
Praxis Precision Medicines
PRAX
$6.85B
$10.1M 2.31%
30,210
+3,887
+15% +$1.23M
2024 Q3
7 quarters
RLAY icon
7
Relay Therapeutics
RLAY
$3.64B
$9.47M 2.16%
506,235
+84,354
+20% +$1.22M
2025 Q2
4 quarters
ALKS icon
8
Alkermes
ALKS
$6.98B
$9.39M 2.14%
179,256
+106,067
+145% +$4.14M
2024 Q4
6 quarters
PCVX icon
9
Vaxcyte
PCVX
$10.2B
$8.7M 1.98%
149,739
+25,092
+20% +$1.36M
2022 Q2
16 quarters
TNGX icon
10
Tango Therapeutics
TNGX
$3.81B
$8.13M 1.85%
260,070
+155,877
+150% +$3.85M
2026 Q1
1 quarter
LQDA icon
11
Liquidia Corp
LQDA
$3.15B
$7.81M 1.78%
97,896
-1,848
-2% -$99K
2024 Q2
8 quarters
COGT icon
12
Cogent Biosciences
COGT
$5.16B
$7.31M 1.67%
188,780
-8,271
-4% -$289K
2022 Q3
15 quarters
GPCR icon
13
Structure Therapeutics
GPCR
$1.5B
$7.02M 1.6%
130,784
+6,875
+6% +$304K
2023 Q3
11 quarters
ELVN icon
14
Enliven Therapeutics
ELVN
$2.78B
$7M 1.6%
137,866
+64,764
+89% +$2.75M
2023 Q2
12 quarters
AMLX icon
15
Amylyx Pharmaceuticals
AMLX
$3.33B
$6.93M 1.58%
386,080
+33,995
+10% +$526K
2025 Q4
2 quarters
SYRE icon
16
Spyre Therapeutics
SYRE
$7.69B
$6.91M 1.57%
77,807
-68,457
-47% -$5M
2023 Q4
10 quarters
LBRX icon
17
LB Pharmaceuticals
LBRX
$1.19B
$6.86M 1.57%
211,511
+37,916
+22% +$1.11M
2025 Q4
2 quarters
CYTK icon
18
Cytokinetics
CYTK
$8.68B
$6.65M 1.52%
78,003
+19,360
+33% +$1.39M
2024 Q3
7 quarters
CCCC icon
19
C4 Therapeutics
CCCC
$349M
$6.3M 1.44%
+1,348,136
New +$4.61M
2026 Q2
0 quarters
TYRA icon
20
Tyra Biosciences
TYRA
$1.3B
$5.9M 1.35%
184,774
+53,470
+41% +$1.77M
2024 Q2
8 quarters
ALMS icon
21
Alumis Inc
ALMS
$792M
$5.63M 1.28%
199,968
+87,039
+77% +$2.03M
2026 Q1
1 quarter
PHVS icon
22
Pharvaris
PHVS
$2B
$5.55M 1.27%
160,494
+62,628
+64% +$1.89M
2025 Q4
2 quarters
TARS icon
23
Tarsus Pharmaceuticals
TARS
$3.21B
$5.48M 1.25%
87,060
+34,596
+66% +$2.21M
2025 Q2
4 quarters
CMPS icon
24
Compass Pathways
CMPS
$1.52B
$5.25M 1.2%
371,120
+6,760
+2% +$68.6K
2025 Q4
2 quarters
DNTH icon
25
Dianthus Therapeutics
DNTH
$4.09B
$4.98M 1.14%
51,125
+15,538
+44% +$1.36M
2024 Q3
7 quarters
1
2 3 4 5

Similar funds

OGM
OnyxPoint Global Management New York $439M AUM 52.19% 1-Year Est. Return
NCM
New Capital Management Houston, Texas $439M AUM 16.55% 1-Year Est. Return
BCC
Bridge City Capital Lake Oswego, Oregon $438M AUM 64.84% 1-Year Est. Return
ASW
Astoria Strategic Wealth Conroe, Texas $438M AUM 16.79% 1-Year Est. Return
CNC
Citizens & Northern Corp Wellsboro, Pennsylvania $438M AUM 26.63% 1-Year Est. Return
TAA
Turiya Advisors Asia Hong Kong $440M AUM 152.81% 1-Year Est. Return
PMA
Prudent Man Advisors Naperville, Illinois $438M AUM 34.49% 1-Year Est. Return
FW
Fairway Wealth Independence, Ohio $437M AUM 19.74% 1-Year Est. Return

HighVista Strategies's Q2 2026 Portfolio in Review

As of Q2 2026, HighVista Strategies held 185 positions worth $439M, up 21% from $362M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

HighVista Strategies's Q2 2026 filing shows 29 new, 50 increased, 66 reduced and 38 closed positions. Its largest new stake was C4 Therapeutics: 1,348,136 shares worth $6.3M. The largest sale was Terns Pharmaceuticals, an estimated $6.03M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 67% a quarter earlier, followed by Technology and Miscellaneous.

  • HighVista Strategies's largest Q2 2026 buy was C4 Therapeutics: 1,348,136 shares worth $6.3M.
  • HighVista Strategies added most to Alkermes in Q2 2026, an estimated $4.14M increase.
  • HighVista Strategies's biggest Q2 2026 reduction was Spyre Therapeutics, cutting an estimated $5M.
  • HighVista Strategies fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $6.03M.
  • HighVista Strategies's ten largest holdings make up 28% of its $439M portfolio in Q2 2026.
  • HighVista Strategies opened 29 new positions and closed 38 in Q2 2026.
  • HighVista Strategies's portfolio value rose 21% quarter-over-quarter to $439M.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.